Effective treatment with dupilumab may allow younger children with severe atopic dermatitis and short stature to catch up on ...

Dupilumab, an injectable interleukin (IL)-4 and IL-13 pathway inhibitor, recently received FDA approval as the first-ever ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and ...

In a major potential step toward personalized therapy for atopic dermatitis, data suggest early, late, and no clinical ...

The following is a summary of “Clinical Effectiveness and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease ...

The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

A new study published in the Journal of American Academy of Dermatology found that Dupilumab improved atopic dermatitis (AD) ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) ...

Learn how dupilumab significantly improves quality of life in COPD patients with type 2 inflammation, according to phase 3 ...

Opens in a new tab or window BOSTON -- Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation had greater improvements in quality of life with dupilumab (Dupixent ...

New trial results show dupilumab significantly improves remission rates and reduces symptoms in patients with bullous ...